Director Steven L. Hoerter of MBX Biosciences, Inc. filed a Form 144 notice of proposed sale on November 10, 2026, covering 4,893 shares of common stock acquired through restricted stock vesting.

Key Highlights

  • Seller: Steven L. Hoerter, identified in the filing as a Director of MBX Biosciences, Inc.
  • Shares proposed for sale: 4,893 shares of common stock, with an aggregate market value of $268,248.45.
  • Acquisition: The 4,893 shares were acquired on November 6, 2026 via restricted stock vesting from the issuer, with payment classified as compensation.
  • Total shares outstanding: 49,656,265 shares of common stock, according to the filing.
  • Purpose of sale: The filing states the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
  • No prior sales: The filing reports nothing to disclose for securities sold during the past three months.
  • Broker: Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917, is named as the executing broker.

Hoerter's Proposed Sale at MBX Biosciences: Filing Details

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 10, 2026, Steven L. Hoerter, a director of MBX Biosciences, Inc. (NASDAQ:MBX), is proposing to sell 4,893 shares of common stock. The filing lists an aggregate market value of $268,248.45 for the shares to be sold, with the approximate date of sale noted as November 10, 2026. The shares are to be sold on the NASDAQ exchange through Fidelity Brokerage Services LLC.

The filing discloses that the 4,893 shares were acquired on November 6, 2026, through a restricted stock vesting transaction from the issuer itself, with the nature of payment listed as compensation. The filing's remarks section states that the proposed sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," indicating the proceeds are at least in part intended to satisfy tax liabilities arising from the equity award.

MBX Biosciences, Inc. is headquartered at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032. The filing reports 49,656,265 total shares of common stock outstanding. No sales by Hoerter during the three months preceding this notice were reported. The Form 144 was signed by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Steven Hoerter.

What Was Disclosed

MBX Biosciences director Steven L. Hoerter filed a Form 144 notice on November 10, 2026, to sell 4,893 shares of common stock acquired through restricted stock vesting on November 6, 2026, partly to cover taxes from the equity award settlement.